PYC PYC Therapeutics Ltd
- 0.135
- +0.020+17.39%
PYC Therapeutics Ltd News
Canaccord Genuity Starts PYC Therapeutics at Buy With AU$0.22 Price Target
04:37 AM EDT, 06/18/2024 (MT Newswires) -- Canaccord Genuity Starts PYC Therapeutics at Buy With AU$0.22 Price Target Price (AUD): $0.11, Change: $-0.01, Percent Change: -4.55%
Why IDP Education, Novonix, PYC, and Regis Resources Share Are Racing Higher
The S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a positive note. In afternoon trade, the benchmark index is up 0.4% to 7,853.5 points.
PYC Therapeutics Advances Groundbreaking Treatment for Phelan-McDermid Syndrome
PYC Therapeutics (ASX: PYC) has made a breakthrough with its main drug candidate for the potential treatment of neurodevelopmental disorder Phelan-McDermid Syndrome (PMS).
PYC Achieved Protein-restoration on Genetic Condition PMS Ahead of Human Trialling
Biotechnology company Pyc Therapeutics Ltd (ASX:PYC) has announced that it has been able to restore a deficient protein causing neurodevelopmental disorder Phelan McDermid Syndrome (or PMS), as part of Pyc’s wider drug development program which will soon involve human trials.
PYC Therapeutics's Fourth Neurodevelopmental Disorder Drug Candidate Moves Closer to Human Trials; Shares Up 10%
PYC Therapeutics (ASX:PYC) said its fourth drug discovery program that aims to address the underlying cause of a severe neurodevelopmental disorder generated data needed to enter human trials, accordi
2 ASX Penny Stocks to Consider Buying While Their Prices Are This Cheap
Investors with a high risk tolerance might want to consider adding the two ASX penny stocks in this article to a balanced portfolio.
Why Appen, Mayne Pharma, Playside, and PYC Shares Are Storming Higher
It has been a tough finish to the week for the S&P/ASX 200 Index (ASX: XJO). In afternoon trade, the benchmark index is down 1.2% to 7,719 points.
PYC Therapeutics Secures US FDA Orphan Drug Designation for Eye Disease Medication Candidate; Shares Fall 4%
PYC Therapeutics (ASX:PYC) secured an orphaned drug designation from the US Food and Drug Administration for the use of its medicinal candidate PYC-001 in patients with autosomal dominant optic atroph
Guess Which ASX All Ords Insider Just Bought 50 Million Shares in Their Company
It can be useful for investors to keep an eye on which shares have experienced meaningful insider buying.
PYC Therapeutics Started at Buy by Bell Potter >PYC.AU
PYC Therapeutics Started at Buy by Bell Potter >PYC.AU
PYC Therapeutics Started With A$0.17/Share Target Price by Bell Potter>PYC.AU
PYC Therapeutics Started With A$0.17/Share Target Price by Bell Potter>PYC.AU
PYC Therapeutics Completes Dosing for Eye Disease Trial; Shares Fall 5%
PYC Therapeutics (ASX:PYC) completed dosing of the fourth cohort for its single ascending dose trial investigating the use of its medication candidate to treat the eye condition retinitis pigmentosa t
Why IDP Education, JB Hi-Fi, PYC, and Renascor Shares Are Falling Today
The S&P/ASX 200 Index (ASX: XJO) is having a day to remember on Thursday. In afternoon trade, the benchmark index is up a sizeable 1.55% to 7,873.9 points.
PYC Therapeutics Price Target Cut 5% to A$0.37/Share by Wilsons
PYC Therapeutics Price Target Cut 5% to A$0.37/Share by Wilsons
Australian Shares Rebound Amid Easing Middle East Tensions, Ahead of Local Inflation Data
Australian shares rose Monday as market sentiment was boosted by easing tensions in the Middle East and as investors awaited a key domestic inflation report due Wednesday. The S&P/ASX 200 Index rose 8
PYC Therapeutics Confirms Safety, Tolerability of Kidney Medication in Animal Study
PYC Therapeutics (ASX:PYC) confirmed the safety and tolerability of its kidney medication candidate, PYC-003, via a study conducted in non-human primates, according to a Monday filing with the Austral
PYC Therapeutics Raises AU$13.5 Million via Retail Offer; AU$21.2 Million Retail Shortfall Placement Announced
PYC Therapeutics (ASX:PYC) raised AU$13.5 million via the retail component of its accelerated non-renounceable entitlement offer, with a further AU$21.2 million retail shortfall to be offered to selec
Here's Why We're Not Too Worried About PYC Therapeutics' (ASX:PYC) Cash Burn Situation
PYC Therapeutics Raises AU$40 Million via Entitlement Offer
PYC Therapeutics (ASX:PYC) secured AU$40 million via the institutional segment of an accelerated non-renounceable entitlement offer (ANREO) disclosed to the public on March 14, according to a Monday f
PYC Therapeutics to Raise Up to AU$75 Million for Advancing Drug Candidates
PYC Therapeutics (ASX:PYC) is seeking to raise up to about AU$74.6 million via a 1-for-4 entitlement offer at AU$0.08 per share. Proceeds will be used to advance the biotechnology company's pipeline o
Analysis
Price Target
No Data
